Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Fusen Pharmaceutical Company Limited
福森藥業有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT "METFORMIN EMPAGLIFLOZIN TABLETS (I)" APPROVED FOR MARKETING

The board (the "**Board**") of directors (the "**Directors**") of Fusen Pharmaceutical Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the "Metformin Empagliflozin Tablets (I)" developed by the Group, has obtained the approval for marketing from the National Medical Products Administration of China for the treatment of the following diseases: in conjunction with diet control and exercise, it is suitable for adult patients with type 2 diabetes who are receiving treatment with Empagliflozin and Metformin Hydrochloride to improve the blood glucose control of such patients.

"Metformin Empagliflozin Tablets (I)" is a compound preparation consisting of Metformin Hydrochloride and Empagliflozin. Its pharmacological effects are as follows: Metformin reduces hepatic glucose production, inhibits intestinal absorption of glucose, and increases the uptake and utilization of glucose in peripheral tissues. It improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Empagliflozin is an SGLT2 inhibitor that reduces renal glucose reabsorption, lowers the renal glucose threshold, and promotes the excretion of glucose in the urine. Both components have a synergistic effect in terms of mechanism and offer better hypoglycemic effect compared to ordinary single preparation.

The National Health Commission of the People's Republic of China has released the latest "Medium and Long-term Plan for the Prevention and Control of Chronic Diseases in China (2017–2025)", which sets the ultimate goals for 2025, according to which, the standardized management rate and core knowledge awareness rate of diabetes patients shall reach 70%, which would lead to an increased demand for diabetes medications. Metformin Empagliflozin Tablets (I) is classified as a Category B medical insurance product and offers advantages such as good hypoglycemic effect, no severe adverse reactions and good patient tolerance. Bioequivalence tests conducted on fasting and postprandial basis have demonstrated that the bioequivalence of this product is consistent with the reference product. Metformin Empagliflozin Tablets (I) provides a very favorable risk-to-benefit ratio for improving blood glucose control of adult patients with type 2 diabetes.

The Directors believe that Metformin Empagliflozin Tablets (I) is another important product for the Group, which further enriches the Group's product pipeline in the field of diabetes treatment. This product will provide a wider range of treatment options for general diabetic patients.

By order of the Board
Fusen Pharmaceutical Company Limited
Cao Zhiming
Chairman and Executive Director

Hong Kong, 15 September 2025

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.